previous
shown
infect
cell
cultur
arenavirus
junv
tacarib
tcrv
promot
phosphoryl
mitogenactiv
protein
kinas
mapk
extracellular
signalregul
kinas
activ
requir
achiev
product
infect
examin
contribut
earli
step
junv
tcrv
multipl
junv
adsorpt
intern
uncoat
affect
treatment
cultur
cell
inhibitor
signal
pathway
contrast
caus
mark
reduct
viral
protein
express
rna
synthesi
junv
rna
synthesi
significantli
augment
presenc
activ
pathway
moreov
impair
express
report
gene
tcrvbase
replicon
system
confirm
abil
compound
hinder
arenaviru
macromolecular
synthesi
use
cellbas
assay
determin
inhibitor
affect
translat
synthet
tcrvlike
mrna
chang
phosphoryl
pattern
translat
factor
found
cell
result
indic
impair
viral
rna
synthesi
therebi
lead
subsequ
reduct
viral
protein
express
thu
conclud
signal
activ
requir
effici
arenaviru
rna
synthesi
arenavirus
envelop
rna
virus
contain
biseg
singlestrand
genom
ambisens
code
strategi
l
segment
code
rnadepend
rna
polymeras
l
small
matrix
protein
z
segment
encod
nucleocapsid
protein
n
glycoprotein
precursor
gpc
member
famili
caus
hemorrhag
fever
diseas
human
repres
import
public
health
concern
endem
region
lassa
lujo
virus
africa
viru
brazil
guanarito
viru
venezuela
machupo
virus
macv
bolivia
viru
junv
argentina
junv
etiolog
agent
argentin
hemorrhag
fever
ahf
administr
immun
plasma
therapeut
intervent
diseas
altern
antivir
therapi
need
due
troubl
maintain
adequ
stock
plasma
absenc
effect
intervent
treat
patient
progress
neurologichemorrhag
phase
develop
implement
vaccin
program
within
endem
area
base
live
attenu
candid
vaccin
markedli
reduc
incid
ahf
nevertheless
candid
recommend
children
pregnant
women
although
vaccin
show
partial
crossprotect
arenaviru
macv
approv
argentina
well
establish
virus
manipul
cell
signal
machineri
benefit
mitogenactiv
protein
kinas
mapk
famili
serinethreonin
kinas
respond
extracellular
stimuli
transduc
signal
cell
membran
nucleu
play
import
role
replic
sever
rna
dna
virus
bestknown
mapk
famili
extracellular
signalregul
kinas
associ
growth
prolifer
signal
cjun
ntermin
kinas
jnk
pathway
involv
respons
environment
inflammatori
stress
main
compon
cascad
three
sequenti
act
kinas
raf
activ
mapk
transloc
nucleu
phosphoryl
transcript
factor
trigger
chang
gene
express
also
mediat
phosphoryl
sever
cytoplasm
substrat
addit
pathway
play
relev
role
replic
sever
virus
regul
innat
immun
respons
viral
infect
base
inhibit
pathway
propos
novel
antivir
strategi
previous
report
junv
infect
induc
biphas
activ
pathway
clear
peak
erk
phosphoryl
first
minut
infect
late
sustain
erk
activ
h
infect
onward
addit
demonstr
treatment
mek
inhibitor
compound
well
silenc
mediat
small
interf
rna
caus
strong
reduct
product
junv
infecti
particl
monkey
human
cell
indic
activ
requir
junv
multipl
moreov
phosphoryl
also
detect
cell
cultur
infect
tacarib
tcrv
picv
arenavirus
treatment
caus
signific
inhibit
tcrv
picv
multipl
investig
role
cascad
arenaviru
infect
perform
detail
analysi
effect
earli
step
junv
tcrv
multipl
vero
cell
grown
modifi
eagl
medium
mem
invitrogen
carlsbad
ca
usa
supplement
newborn
calf
serum
nbc
gentamicin
bsr
cell
clone
cell
grown
use
glasgow
minimum
essenti
medium
gmem
invitrogen
supplement
glutamin
mm
fetal
calf
serum
fc
invitrogen
penicillin
uml
streptomycin
invitrogen
experi
perform
serumfre
medium
attenu
strain
junv
handl
biosafeti
level
train
personnel
vaccin
candid
live
attenu
vaccin
junv
stock
obtain
cell
viral
infect
assay
vero
cell
plaqu
format
assay
use
mem
supplement
nbc
methylcellulos
gentamicin
cell
signal
technolog
danver
usa
ribavirin
sigmaaldrich
st
loui
mi
usa
phorbol
pma
sigmaaldrich
prepar
dimethyl
sulfoxid
dmso
dilut
serumfre
medium
use
percentag
dmso
dilut
serumfre
medium
use
control
untreat
cultur
mous
antijunv
protein
monoclon
antibodi
mab
use
primari
antibodi
immunofluoresc
assay
goat
antimous
igg
conjug
fluorescein
isothiocyan
fitc
sigmaaldrich
use
secondari
antibodi
western
blot
analysi
perform
employ
mous
anti
junv
n
protein
mab
rabbit
anti
perk
cell
signal
anti
erk
santa
cruz
biotechnolog
dalla
tx
usa
anti
cell
signal
antibodi
peroxidas
antirabbit
igg
amersham
littl
chalfont
buckinghamshir
uk
peroxidas
antimous
ig
g
sigmaaldrich
use
secondari
antibodi
plasmid
ptcrv
n
ptcrv
l
express
tcrv
n
l
protein
respect
previous
construct
plasmid
pmgfluc
express
minigenom
design
mgfluc
analog
tcrv
genom
segment
compris
firefli
luciferas
fluc
open
read
frame
orf
antisens
orient
flank
complet
genom
noncod
sequenc
plasmid
express
transcript
mimic
wildtyp
tcrv
n
mrna
plasmid
express
celllik
mrna
name
bear
untransl
region
utr
human
mrna
poli
tract
flank
fluc
orf
plasmid
prluc
use
gener
synthet
mrna
express
renilla
reniformi
luciferas
enzym
rluc
previous
construct
plasmid
express
bacteriophag
rna
polymeras
control
cytomegaloviru
promot
kindli
provid
martin
billet
univers
zurich
irchel
switzerland
vero
cell
preincub
mem
contain
min
infect
multipl
infect
moi
pfucel
presenc
absenc
h
c
follow
extens
wash
cell
lyse
cycl
freez
thaw
cell
debri
remov
low
speed
centrifug
viral
titer
supernat
quantifi
plaqu
assay
vero
cell
pretreat
mem
contain
chlorpromazin
cz
min
cultur
infect
approxim
pfu
junv
presenc
absenc
cz
h
c
viral
adsorpt
cultur
incub
c
differ
time
point
cell
wash
citric
buffer
ph
min
inactiv
nonintern
viral
particl
final
cell
cover
mem
contain
methylcellulos
intern
virion
quantifi
plaqu
format
assay
vero
cell
infect
approxim
pfu
junv
h
c
cultur
transfer
c
differ
time
point
mm
ad
h
treatment
cell
wash
citric
buffer
ph
min
elimin
nonintern
virion
cultur
cover
mem
contain
methylcellulos
assess
number
uncoat
viral
particl
plaqu
format
assay
junv
infect
vero
cell
bsr
cell
transfect
plasmid
use
replicon
assay
treat
differ
time
cell
viabil
determin
abil
live
cell
cleav
tetrazolium
salt
mtt
tetrazolium
bromid
sigmaaldrich
junv
infect
vero
cell
bsr
cell
transfect
plasmid
constitut
tcrvreplicon
system
treat
lyse
sampl
buffer
bio
rad
hercul
ca
usa
express
perk
erk
viral
n
protein
analyz
western
blot
sdspage
perform
polyacrylamid
gel
protein
transfer
pvdf
membran
hybond
p
pharmacia
amersham
uk
membran
incub
trisbuff
salin
tb
contain
bovin
serum
albumin
block
buffer
h
c
follow
overnight
incub
c
primari
antibodi
dilut
block
buffer
sever
wash
membran
incub
h
room
temperatur
secondari
antibodi
dilut
block
buffer
protein
band
visual
chemiluminesc
detect
use
western
lightn
ecl
perkinelm
waltham
usa
quantifi
use
imag
j
http
imagejnetwelcom
window
total
immunofluoresc
assay
cell
monolay
wash
three
time
phosphat
buffer
salin
pb
fix
paraformaldehyd
pb
min
room
temperatur
permeabil
incub
pb
contain
triton
min
room
temperatur
cell
incub
primari
antibodi
min
c
three
wash
pb
incub
secondari
antibodi
min
c
perform
three
wash
pb
cell
nuclei
stain
hoechst
reagent
coverslip
mount
glycerin
solut
pb
ph
contain
octan
dabco
sigmaaldrich
visual
fluoresc
microscop
membran
immunofluoresc
procedur
except
cell
permeabil
triton
omit
percentag
infect
cell
sampl
obtain
count
least
cell
random
select
field
magnif
ad
junv
infect
cell
differ
time
point
h
infect
cell
treat
min
acid
ph
mem
ph
incub
medium
neutral
ph
h
postinfect
pi
cell
fix
methanol
room
temperatur
min
stain
giemsa
pb
min
cell
visual
optic
microscop
number
size
syncytia
sampl
calcul
count
least
nuclei
random
select
field
magnif
total
rna
extract
use
tri
reagent
genbiotech
antib
franc
detect
junv
genom
rna
pcr
perform
previous
describ
briefli
cdna
synthes
use
primer
n
tcrv
revers
genet
system
previous
describ
briefli
bsr
cell
grown
micropl
transfect
use
lipofectamin
reagent
invitrogen
amount
per
well
plasmid
ptcrv
n
ptcrv
l
plasmid
pmgfluc
npand
lexpress
plasmid
omit
control
cell
cultur
rluc
report
vector
prltk
promega
madison
wi
usa
ngwell
ad
transfect
mix
order
estim
transfect
effici
h
posttransfect
supernat
remov
cell
wash
twice
pb
incub
presenc
absenc
h
c
quantif
fluc
rluc
activ
glomax
multi
detect
system
promega
perform
use
dualluciferas
report
assay
system
promega
sampl
fluc
activ
normal
rluc
activ
background
signal
measur
control
cell
cultur
subtract
data
obtain
cultur
transfect
complet
set
plasmid
cap
synthet
rna
obtain
vitro
transcript
promotercontrol
construct
viruslik
mrna
mimick
tcrv
n
mrna
compris
viral
utr
fuse
report
fluc
open
read
frame
follow
viral
utr
celllik
transcript
bear
utr
human
poli
tail
flank
fluc
code
sequenc
bsr
cell
grown
plate
transfect
indic
synthet
mrna
ngwell
along
rluc
mrna
ngwell
use
lipofectamin
reagent
thermo
fisher
scientif
waltham
usa
serumfre
medium
gmem
describ
previous
three
hour
later
transfect
mix
remov
cell
monolay
wash
gmem
incub
gmem
contain
incub
proceed
h
c
quantif
fluc
rluc
activ
perform
describ
statist
signific
differ
untreat
drugtreat
cultur
determin
either
pair
student
test
compar
result
two
group
anova
analysi
three
independ
experi
analyz
unless
state
otherwis
p
valu
consid
statist
signific
clade
b
new
world
nw
arenavirus
includ
junv
tcrv
use
transferrin
receptor
bind
cell
surfac
allow
viral
intern
endocyt
pathway
viral
particl
intern
acid
ph
endosom
compart
trigger
fusion
viral
endosom
membran
lead
releas
viral
nucleocapsid
cytoplasm
sinc
previous
prove
junv
infect
induc
earli
activ
erk
pathway
wonder
whether
mapk
may
involv
initi
event
viral
multipl
cycl
therefor
first
analyz
effect
mek
inhibitor
junv
adsorpt
shown
figur
presenc
affect
amount
junv
infecti
particl
adsorb
vero
cell
h
incub
c
investig
effect
inhibitor
viral
intern
junv
adsorpt
cultur
incub
c
differ
time
period
presenc
absenc
chlorpromazin
cz
inhibitor
clathrinmedi
endocytosi
wherea
cz
block
junv
endocyt
uptak
signific
differ
kinet
junv
intern
detect
treat
cultur
respect
untreat
one
figur
order
assess
whether
inhibit
mek
affect
viral
uncoat
junv
adsorb
c
cell
transfer
c
differ
time
point
either
nh
cl
compound
rais
endosom
ph
therebi
inhibit
releas
viral
nucleocapsid
ad
maintain
h
uncoat
viral
particl
quantifi
plaqu
assay
expect
nh
cl
significantli
inhibit
junv
uncoat
even
ad
min
postadsorpt
contrari
uncoat
process
affect
treatment
figur
uncov
viral
step
mapk
engag
first
analyz
effect
time
addit
express
n
protein
infect
cell
examin
h
pi
order
detect
level
viral
protein
accumul
along
one
cycl
viral
multipl
lack
cytotox
treatment
assess
mtt
method
figur
addit
compound
h
pi
associ
highli
reduc
level
n
express
likewis
mark
reduct
amount
n
detect
addit
inhibitor
h
pi
figur
consist
cell
treat
h
pi
exhibit
signific
reduct
extracellular
viru
yield
respect
untreat
cell
maximum
inhibit
also
observ
addit
compound
h
pi
figur
result
correl
undetect
amount
phosphoryl
erk
figur
upper
panel
indic
mapk
involv
postentri
step
affect
n
express
viru
product
next
sought
evalu
impact
mapk
activ
express
function
viral
glycoprotein
gpc
glycoprotein
precursor
cleav
host
proteas
produc
stabl
signal
peptid
ssp
receptor
bind
transmembran
subunit
mediat
low
phdepend
fusion
viral
envelop
endosom
membran
analyz
effect
cytoplasm
plasma
membran
express
viral
glycoprotein
surfac
total
immunofluoresc
assay
perform
seen
figur
b
similarli
reduc
percentag
cell
exhibit
either
total
membran
fluoresc
indic
compound
mainli
affect
synthesi
junv
glycoprotein
rather
glycoprotein
transport
cell
surfac
accordingli
abil
glycoprotein
complex
mediat
low
ph
membran
fusion
evalu
wellestablish
cellcel
fusion
test
signific
decreas
number
size
syncytia
observ
cell
compar
untreat
cultur
figur
overal
result
indic
mapk
requir
express
nucleoprotein
viral
envelop
glycoprotein
next
investig
effect
treatment
junv
rna
synthesi
perform
quantit
rtpcr
assay
detect
genom
rna
figur
b
signific
reduct
amount
viral
rna
evid
treatment
junvinfect
cell
compar
effect
caus
ribavirin
use
refer
rna
synthesi
inhibitor
contrast
treatment
pma
known
activ
pathway
prove
promot
junv
product
strongli
increas
junv
rna
synthesi
compar
untreat
control
figur
previous
demonstr
affect
junv
product
infect
also
inhibit
multipl
nonpathogen
nw
arenavirus
tcrv
picv
use
tcrv
replicon
system
assess
relev
erk
pathway
activ
synthesi
arenaviru
rna
system
coexpress
nucleoprotein
n
viral
rna
polymeras
l
suffici
promot
fullcycl
rna
replic
tcrv
segment
analog
thu
investig
action
mek
inhibitor
express
tcrv
genom
analog
mgfluc
contain
fluc
report
gene
complet
tcrv
rna
noncod
sequenc
figur
treatment
fluc
express
significantli
reduc
respect
untreat
cultur
figur
importantli
blockad
pathway
alter
n
protein
express
level
transfect
cell
figur
indic
protein
express
plasmid
constitut
replicon
system
affect
presenc
mek
inhibitor
addit
lack
cytotox
treatment
transfect
bsr
cell
also
corrobor
mtt
method
figur
altogeth
result
indic
impair
report
gene
express
tcrv
genom
analog
support
mapk
display
import
role
viral
rna
synthesi
complet
igr
fluc
orf
antisens
orient
complet
genom
utr
bsr
cell
plasmidtransfect
coexpress
tcrv
n
l
protein
along
mgfluc
rna
transfect
mix
includ
plasmid
express
rluc
control
transfect
effici
remov
h
cell
incub
presenc
cytoplasm
extract
obtain
h
posttransfect
assay
fluc
rluc
activ
fluc
activ
data
normal
correspond
rluc
level
mean
normal
fluc
valu
sd
two
independ
experi
perform
triplic
shown
percentag
data
correspond
untreat
cultur
taken
pair
student
test
p
e
western
blot
analysi
n
protein
perk
level
sampl
obtain
bsr
cell
transfect
mgfluc
express
n
l
presenc
absenc
describ
erk
detect
use
load
control
reduc
level
fluc
activ
observ
context
replicon
system
treat
cultur
could
ascrib
blockad
rna
synthesi
ineffici
translat
fluc
mrna
order
distinguish
possibl
perform
cellbas
translat
assay
analyz
effect
pathway
inhibit
translat
cap
synthet
transcript
use
viruslik
mrna
mimic
tcrv
n
mrna
compris
fluc
orf
flank
viral
utr
figur
control
celllik
mrna
bear
utr
human
mrna
poli
tail
flank
fluc
code
sequenc
also
includ
experi
figur
translat
virusor
celllik
transcript
examin
transfect
bsr
cell
follow
treatment
wherea
express
celllik
mrna
slightli
decreas
viruslik
mrna
translat
level
treat
cultur
significantli
differ
untreat
cell
figur
suggest
inhibit
viral
rna
synthesi
junv
genom
figur
fluc
express
genom
analog
figur
reli
advers
effect
compound
viral
mrna
translat
eukaryot
initi
factor
cell
factor
essenti
initi
step
protein
translat
activ
hypophosphoryl
state
describ
inhibitor
may
promot
phosphoryl
therebi
inhibit
cell
translat
process
thu
analyz
whether
inhibit
could
link
increas
phosphoryl
sought
quantifi
level
phosphoryl
upon
treatment
junv
infect
vero
cell
h
accord
data
previous
report
absenc
level
phosphoryl
junvinfect
cell
compar
uninfect
cultur
determin
western
blot
analysi
addit
inhibit
pathway
induc
chang
amount
phosphoryl
either
uninfect
junv
infect
cell
figur
result
support
inhibit
viral
protein
express
rna
synthesi
observ
treat
cultur
would
relat
increas
phosphoryl
host
cell
although
well
establish
signal
involv
multipl
sever
anim
virus
much
remain
understood
specif
role
transduct
cascad
play
viral
replic
cycl
present
studi
analyz
inhibitori
effect
inhibitor
mek
compon
signal
pathway
earli
event
junv
multipl
prove
earli
activ
erk
signal
requir
junv
adsorpt
intern
uncoat
figur
contrast
treatment
infect
cell
caus
mark
suppress
viral
protein
rna
product
figur
hand
junv
rna
synthesi
significantli
augment
presenc
activ
pathway
figur
find
strongli
support
analysi
effect
tcrvbase
revers
genet
system
figur
cellbas
translat
assay
reveal
translat
tcrvlike
mrna
remain
unaffect
presenc
figur
provid
evid
inhibitor
would
impair
viral
rna
synthesi
therebi
lead
subsequ
reduct
viral
protein
express
despit
lack
signific
inhibitori
effect
viruslik
mrna
translat
translat
celllik
mrna
appear
moder
reduc
cell
treat
mek
inhibitor
figur
howev
minor
advers
effect
would
seem
relev
cell
translat
effici
inde
level
viral
protein
express
context
replicon
system
erk
level
infect
cell
unaffect
mek
inhibitor
figur
pathway
regul
cellular
gene
transcript
also
exert
posttranscript
control
certain
mrna
aurich
element
contain
mrna
encod
varieti
protein
involv
cell
prolifer
inflammatoryimmun
respons
therefor
possibl
may
downregul
translat
subset
cellular
mrna
without
affect
express
transcript
includ
n
protein
transcript
rule
moreov
demonstr
treatment
promot
increment
amount
phosphoryl
regardless
viru
infect
figur
summari
data
reveal
inhibit
independ
phosphoryl
link
alter
host
translat
level
support
mapk
play
import
role
viral
rna
synthesi
agreement
find
cai
et
al
show
hinder
synthesi
mous
hepat
viru
mhv
genom
subgenom
rna
wherea
viral
entri
translat
mhv
mrna
appear
unaffect
mek
inhibitor
great
deal
knowledg
pathway
particip
replic
rna
virus
come
studi
influenza
iva
b
ivb
virus
lack
effect
earli
step
junv
multipl
agreement
data
obtain
marjuki
et
al
iva
infect
cell
howev
contrast
result
mek
inhibit
affect
synthesi
iva
ivb
rna
impair
export
newli
synthes
viral
ribonucleoprotein
rnp
cell
nucleu
cytoplasm
hinder
viral
assembl
even
though
erkmedi
phosphoryl
iva
protein
report
requir
phosphoryl
rnp
transport
nucleu
cytoplasm
demonstr
addit
propos
host
cell
factor
regul
erk
phosphoryl
might
involv
export
iv
rnp
analysi
junv
n
amino
acid
sequenc
use
phosphomotif
finder
program
reveal
junv
nucleoprotein
contain
three
potenti
phosphoryl
motif
previous
demonstr
selfassoci
n
protein
molecul
well
interact
n
l
protein
requir
sustain
transcript
replic
tcrv
mg
rna
therefor
either
direct
phosphoryl
erk
erkregul
phosphoryl
n
might
relev
format
andor
activ
viral
protein
complex
carri
viral
rna
synthesi
henc
block
erk
signal
might
hinder
n
phosphoryl
therebi
inhibit
junv
genom
replic
inde
two
residu
nucleoprotein
arenaviru
lymphocyt
choriomening
viru
lcmv
conserv
everi
mammalian
arenaviru
demonstr
requir
recombin
lcmv
recoveri
suggest
involv
regul
viral
rna
replic
besid
requir
coordin
interact
n
l
viral
rna
arenaviru
rna
synthesi
like
involv
interact
host
cell
factor
prohibitin
phb
one
upstream
compon
pathway
prove
interact
junv
lcmv
n
protein
recent
prove
phb
inhibitor
rocaglamid
impair
lcmv
rna
synthesi
moreov
junv
multipl
also
inhibit
rocaglamid
provid
evid
relev
pathway
activ
arenaviru
rna
synthesi
thu
yet
unknown
cellular
protein
possibl
part
viral
transcriptasereplicas
complex
may
target
regul
phosphoryl
found
evid
presenc
mek
inhibitor
h
pi
caus
decreas
viral
rna
synthesi
figur
inhibit
viru
product
figur
hand
treatment
h
pi
littl
effect
n
protein
express
figur
caus
around
reduct
viru
yield
figur
interestingli
inhibit
phb
rocaglamid
affect
lcmv
rna
synthesi
also
bud
lcmv
viruslik
particl
regard
possibl
pathway
may
engag
late
step
viru
multipl
cycl
bud
releas
viral
particl
discard
remain
assess
recent
advanc
knowledg
arenaviru
biolog
greatli
contribut
discoveri
novel
antivir
strategi
modul
arenavirus
make
signal
pathway
attract
target
antivir
intervent
repres
strategi
low
risk
viral
resist
appear
could
effect
differ
arenavirus
moreov
antivir
cellular
target
offer
possibl
repurpos
licens
compound
approv
treat
human
diseas
promis
mek
inhibitor
known
safetydata
profil
actual
evalu
cancer
clinic
trial
experi
perform
present
studi
order
identifi
step
junv
tcrv
replic
cycl
exert
inhibitori
action
indic
signal
import
effici
viral
rna
synthesi
investig
assess
whether
erk
activ
induc
chang
phosphoryl
state
either
viral
cellular
factor
help
identifi
cellular
erk
target
involv
viral
rna
product
follow
avail
onlin
http
figur
effect
treatment
viabil
junv
infect
vero
cell
figur
effect
treatment
viabil
bsr
cell
